EGFR and metastatic neoplasm: In a multiple logistic regression model, the anti-EGFR free interval >16 months as well as the anti-EGFR free interval >14, among the variables (i.e., long anti-EGFR free interval, previous response to anti-EGFR treatment, and previous lines >2 for metastatic disease), maintained their independent role for OS (p = 0.033 and p = 0.028, respectively).